Hepatology,
Год журнала:
2020,
Номер
72(5), С. 1605 - 1616
Опубликована: Фев. 11, 2020
Chronic
hepatitis
B
virus
(HBV),
C
(HCV),
nonalcoholic
fatty
liver
disease
(NAFLD),
and
alcohol-associated
(ALD)
are
main
causes
of
chronic
disease.
We
assessed
the
global
incidence,
mortality,
disability-adjusted
life-years
(DALYs)
related
to
(primary
cancer
[LC]
cirrhosis).We
obtained
data
from
2017
Global
Burden
Disease
study.
In
2017,
there
were
2.14
million
liver-related
deaths
(2.06-2.30
million),
representing
an
11.4%
increase
since
2012
(16.0%
in
LC
deaths;
8.7%
cirrhosis
deaths).
accounted
for
38.3%
61.7%,
respectively,
(LC
HBV
[39%
29%],
HCV
[29%
26%],
ALD
[16%
25%],
NAFLD
[8%
9%]).
Between
age-standardized
incidence
rate,
death
rate
(ASDR),
DALY
increased
11.1
11.8,
10.1
10.2,
250.4
253.6
per
100,000,
respectively.
Although
66.0
66.3,
ASDR
decreased
17.1
16.5
532.9
510.7,
The
largest
occurred
Eastern
Europe
(annual
percent
change
[APC]
=
2.18%
[0.89%-3.49%]),
whereas
decrease
high-income
Asia
Pacific
(APC
-2.88%
[-3.58
-2.18%]).
LC-NAFLD
annually
by
1.42%
(1.00%-1.83%)
0.53%
(0.08-0.89),
no
increases
(P
0.224)
0.054).
cirrhosis-NAFLD
0.29%
[0.01%-0.59%])
but
-0.44%
[-0.78%
-0.40%]),
-0.50%
[-0.81%
-0.18%]),
-1.43%
[-1.71%
-0.40%]).From
burden
has
increased.
Viral
remains
most
common
cause
deaths,
is
rapidly
growing
contributor
mortality
morbidity.
Hepatology,
Год журнала:
2018,
Номер
69(6), С. 2672 - 2682
Опубликована: Сен. 4, 2018
Over
the
past
2
decades,
nonalcoholic
fatty
liver
disease
(NAFLD)
has
grown
from
a
relatively
unknown
to
most
common
cause
of
chronic
in
world.
In
fact,
25%
world’s
population
is
currently
thought
have
NAFLD.
Nonalcoholic
steatohepatitis
(NASH)
subtype
NAFLD
that
can
progress
cirrhosis,
hepatocellular
carcinoma
(HCC),
and
death.
NASH
are
not
only
found
adults—there
also
high
prevalence
these
diseases
children
adolescents.
Because
close
association
with
type
diabetes
(T2DM)
obesity,
latest
models
predict
will
increase,
causing
tremendous
clinical
economic
burden
poor
patient‐reported
outcomes.
Nonetheless,
there
no
accurate
noninvasive
method
detect
NASH,
treatment
this
limited
lifestyle
modifications.
To
examine
state
among
different
regions
understand
global
trajectory
disease,
an
international
group
experts
came
together
during
2017
American
Association
for
Study
Liver
Diseases
Global
Forum.
We
provide
summary
forum
assessment
current
worldwide.
Journal of Hepatology,
Год журнала:
2018,
Номер
69(4), С. 896 - 904
Опубликована: Июнь 7, 2018
Non-alcoholic
fatty
liver
disease
(NAFLD)
and
non-alcoholic
steatohepatitis
(NASH)
are
increasingly
a
cause
of
cirrhosis
hepatocellular
carcinoma
globally.
This
burden
is
expected
to
increase
as
epidemics
obesity,
diabetes
metabolic
syndrome
continue
grow.
The
goal
this
analysis
was
use
Markov
model
forecast
NAFLD
using
currently
available
data.A
used
estimate
NASH
progression
in
eight
countries
based
on
data
for
adult
prevalence
obesity
type
2
mellitus
(DM).
Published
estimates
expert
consensus
were
build
validate
the
projections.If
DM
level
off
future,
we
project
modest
growth
total
cases
(0-30%),
between
2016-2030,
with
highest
China
result
urbanization
lowest
Japan
shrinking
population.
However,
at
same
time,
will
15-56%,
while
mortality
advanced
more
than
double
an
aging/increasing
population.NAFLD
represent
large
growing
public
health
problem
efforts
understand
epidemic
mitigate
needed.
If
current
historical
rates,
both
increase.
Since
reversible,
campaigns
awareness
diagnosis,
promote
diet
exercise
can
help
manage
future
burden.Non-alcoholic
lead
disease.
Both
conditions
becoming
prevalent
A
mathematical
built
how
associated
change
over
time.
Results
suggest
increasing
liver-related
coming
years.
Hepatology,
Год журнала:
2023,
Номер
77(4), С. 1335 - 1347
Опубликована: Янв. 3, 2023
Background
and
Aims:
NAFLD
is
a
leading
cause
of
liver-related
morbidity
mortality.
We
assessed
the
global
regional
prevalence,
incidence,
mortality
using
an
in-depth
meta-analytic
approach.
Approach
Results:
PubMed
Ovid
MEDLINE
were
searched
for
population-based
studies
from
1990
to
2019
survey
year
(last
published
2022)
per
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
(PRISMA).
Meta-analysis
was
conducted
random-effects
models.
Bias
risk
assessment
Joanna
Briggs
Institute.
Of
2585
reviewed,
92
(N=9,361,716)
met
eligibility
criteria.
Across
study
period
(1990–2019),
pooling
prevalence
estimates
ultrasound-defined
yielded
overall
30.05%
(95%
CI:
27.88%–32.32%)
30.69%
(28.4–33.09),
respectively.
Global
increased
by
+50.4%
25.26%
(21.59–29.33)
in
1990–2006
38.00%
(33.71–42.49)
2016–2019
(
p
<0.001);
+38.7%
25.16%
(19.46–31.87)
34.59%
(29.05–40.57)
=0.029).
The
highest
Latin
America
44.37%
(30.66%–59.00%),
then
Middle
East
North
Africa
(MENA)
(36.53%,
28.63%–45.22%),
South
Asia
(33.83%,
22.91%–46.79%),
South-East
(33.07%,
18.99%–51.03%),
(31.20%,
25.86%–37.08%),
(29.71%,
25.96%–33.76%),
Pacific
28.02%
(24.69%–31.60%),
Western
Europe
25.10%
(20.55%–30.28%).
Among
cohort
diagnosed
without
liver
biopsy,
pooled
rate
1000
PY
12.60
(6.68–23.67)
all-cause
mortality;
4.20
(1.34–7.05)
cardiac-specific
2.83
(0.78–4.88)
extrahepatic
cancer-specific
0.92
(0.00–2.21)
liver-specific
Conclusions:
30%
increasing
which
requires
urgent
comprehensive
strategies
raise
awareness
address
all
aspects
on
local,
regional,
levels.
